Oral pH-modified release budesonide for treatment of inflammatory bowel disease, collagenous and lymphocytic colitis
Author:
- 21 April 2008
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 9 (7) , 1257-1265
Abstract
Background: Budesonide is a glucocorticoid with high topical glucocorticoid activity and low systemic availability. Oral pH-modified release budesonide has been investigated for the treatment of various inflammatory intestinal diseases. Objective: To summarise the investigational data of oral pH-modified release budesonide for the treatment of Crohn's disease, ulcerative colitis, collagenous colitis and lymphocytic colitis. Methods: Assessment of all published (full paper or meeting abstract) clinical studies with oral pH-modified release budesonide for the treatment of inflammatory intestinal diseases. Results/conclusion: Oral pH-modified release budesonide induces remission in mild-to-moderately active Crohn's disease of the ileum and/or ascending colon. This drug is useful to replace conventional systemic glucocorticoids in patients with ileocoecal Crohn's disease. Open-label studies showed efficacy in ulcerative colitis, but this finding has to be confirmed in controlled trials. Oral pH-modified relea...Keywords
This publication has 39 references indexed in Scilit:
- Oral budesonide in the treatment of chronic refractory pouchitisAlimentary Pharmacology & Therapeutics, 2007
- Pharmacokinetics and pharmacodynamic action of budesonide in children with Crohn's diseaseAlimentary Pharmacology & Therapeutics, 2006
- Budesonide as maintenance treatment in Crohn's disease: a placebo‐controlled trialAlimentary Pharmacology & Therapeutics, 2005
- Systematic review: the effectiveness of budesonide therapy for Crohn's diseaseAlimentary Pharmacology & Therapeutics, 2002
- Maintenance of Crohn’s disease over 12 months: fixed versus flexible dosing regimen using budesonide controlled ileal release capsulesAlimentary Pharmacology & Therapeutics, 2001
- Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's diseaseGut, 2001
- Bone turnover during short‐term therapy with methylprednisolone or budesonide in Crohn’s diseaseAlimentary Pharmacology & Therapeutics, 1998
- Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn’s diseaseGut, 1998
- Oral budesonide as maintenance therapy in Crohn’s disease—results of a 12‐month studyAlimentary Pharmacology & Therapeutics, 1998
- Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study.Gut, 1996